Astellas Reports P-III (MOONLIGHT 3) Trial Results of Fezolinetant for the Treatment of Vasomotor Symptoms Associated with Menopause
Shots:
- The P-III (MOONLIGHT 3) trial evaluating the long-term safety and tolerability of fezolinetant (30mg, qd) vs PBO in 150 women with VMS associated with menopause at 34 sites in mainland China
- The 1EPs of the study are the frequency and severity of AEs that were generally consistent with prior P-III studies of fezolinetant
- Fezolinetant is a selective neurokinin-3 (NK3) receptor antagonist & inhibits NKB binding on KNDy neurons to neuronal activity in the thermoregulatory center of the brain reducing the frequency and severity. Additionally, fezolinetant’s NDA is currently under review for VMS associated with menopause in the US
Ref: PRNewswire | Image: Astellas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
